Technical Analysis for LPCN - Lipocine Inc.

Grade Last Price % Change Price Change
F 5.10 8.28% 0.39
LPCN closed down 1.05 percent on Wednesday, November 20, 2024, on 16 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Flat Up

Date Alert Name Type % Chg
Outside Day Range Expansion 8.28%
Wide Bands Range Expansion 8.28%
Oversold Stochastic Weakness 8.28%
Inside Day Range Contraction 7.14%
Wide Bands Range Expansion 7.14%
Oversold Stochastic Weakness 7.14%
MACD Bearish Centerline Cross Bearish 8.05%
Stochastic Reached Oversold Weakness 8.05%
Lower Bollinger Band Touch Weakness 8.05%
Oversold Stochastic Weakness 8.05%

   Recent Intraday Alerts

Alert Time
Rose Above 50 DMA 7 minutes ago
10 DMA Resistance about 1 hour ago
Rose Above Previous Day's High about 2 hours ago
Up 5% about 2 hours ago
Rose Above 10 DMA about 3 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lipocine Inc. Description

Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth

Is LPCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.79
52 Week Low 2.38
Average Volume 32,561
200-Day Moving Average 5.28
50-Day Moving Average 5.08
20-Day Moving Average 5.39
10-Day Moving Average 5.03
Average True Range 0.46
RSI (14) 41.18
ADX 27.62
+DI 11.30
-DI 17.86
Chandelier Exit (Long, 3 ATRs) 4.79
Chandelier Exit (Short, 3 ATRs) 6.01
Upper Bollinger Bands 6.30
Lower Bollinger Band 4.49
Percent B (%b) 0.12
BandWidth 33.59
MACD Line -0.10
MACD Signal Line 0.03
MACD Histogram -0.13
Fundamentals Value
Market Cap 25.04 Million
Num Shares 5.32 Million
EPS -3.21
Price-to-Earnings (P/E) Ratio -1.47
Price-to-Sales 2.36
Price-to-Book 0.95
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.22
Resistance 3 (R3) 5.26 5.12 5.14
Resistance 2 (R2) 5.12 4.99 5.10 5.11
Resistance 1 (R1) 4.91 4.91 4.85 4.88 5.08
Pivot Point 4.78 4.78 4.74 4.76 4.78
Support 1 (S1) 4.57 4.65 4.50 4.54 4.34
Support 2 (S2) 4.43 4.56 4.42 4.31
Support 3 (S3) 4.23 4.43 4.28
Support 4 (S4) 4.20